The RARE 2 trial, sponsored by the National Cancer Institute, is investigating the combination of talazoparib, a PARP inhibitor, and temozolomide, an alkylating agent, in patients with advanced rare solid tumors. This trial addresses a niche market segment with limited treatment options, potentially positioning the combination therapy as a viable treatment for patients with rare cancers that have progressed on standard therapies. The outcomes of this trial could influence competitive positioning against existing therapies and inform future development strategies for similar combinations in oncology. Given the rarity of the target patient population, successful results may lead to expedited regulatory pathways and increased interest from pharmaceutical partners seeking to expand their oncology portfolios.